BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 25662504)

  • 1. A leak pathway for luminal protons in endosomes drives oncogenic signalling in glioblastoma.
    Kondapalli KC; Llongueras JP; Capilla-González V; Prasad H; Hack A; Smith C; Guerrero-Cázares H; Quiñones-Hinojosa A; Rao R
    Nat Commun; 2015 Feb; 6():6289. PubMed ID: 25662504
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MicroRNA-135a regulates NHE9 to inhibit proliferation and migration of glioblastoma cells.
    Gomez Zubieta DM; Hamood MA; Beydoun R; Pall AE; Kondapalli KC
    Cell Commun Signal; 2017 Dec; 15(1):55. PubMed ID: 29268774
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A gain of function paradox: Targeted therapy for glioblastoma associated with abnormal NHE9 expression.
    Pall AE; Juratli L; Guntur D; Bandyopadhyay K; Kondapalli KC
    J Cell Mol Med; 2019 Nov; 23(11):7859-7872. PubMed ID: 31532058
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Emerging links between endosomal pH and cancer.
    Ko M; Quiñones-Hinojosa A; Rao R
    Cancer Metastasis Rev; 2020 Jun; 39(2):519-534. PubMed ID: 32253638
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DSE promotes aggressive glioma cell phenotypes by enhancing HB-EGF/ErbB signaling.
    Liao WC; Liao CK; Tsai YH; Tseng TJ; Chuang LC; Lan CT; Chang HM; Liu CH
    PLoS One; 2018; 13(6):e0198364. PubMed ID: 29864158
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting OSMR in glioma stem cells.
    Mohan S; Bonni A; Jahani-Asl A
    Oncotarget; 2017 Mar; 8(10):16103-16104. PubMed ID: 28177884
    [No Abstract]   [Full Text] [Related]  

  • 7. Role of glycosyltransferase PomGnT1 in glioblastoma progression.
    Lan J; Guo P; Lin Y; Mao Q; Guo L; Ge J; Li X; Jiang J; Lin X; Qiu Y
    Neuro Oncol; 2015 Feb; 17(2):211-22. PubMed ID: 25085363
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Erlotinib resistance in EGFR-amplified glioblastoma cells is associated with upregulation of EGFRvIII and PI3Kp110δ.
    Schulte A; Liffers K; Kathagen A; Riethdorf S; Zapf S; Merlo A; Kolbe K; Westphal M; Lamszus K
    Neuro Oncol; 2013 Oct; 15(10):1289-301. PubMed ID: 23877316
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Afatinib and Temozolomide combination inhibits tumorigenesis by targeting EGFRvIII-cMet signaling in glioblastoma cells.
    Vengoji R; Macha MA; Nimmakayala RK; Rachagani S; Siddiqui JA; Mallya K; Gorantla S; Jain M; Ponnusamy MP; Batra SK; Shonka N
    J Exp Clin Cancer Res; 2019 Jun; 38(1):266. PubMed ID: 31215502
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The EGFR inhibitor gefitinib suppresses ligand-stimulated endocytosis of EGFR via the early/late endocytic pathway in non-small cell lung cancer cell lines.
    Nishimura Y; Bereczky B; Ono M
    Histochem Cell Biol; 2007 May; 127(5):541-53. PubMed ID: 17361439
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fyn and SRC are effectors of oncogenic epidermal growth factor receptor signaling in glioblastoma patients.
    Lu KV; Zhu S; Cvrljevic A; Huang TT; Sarkaria S; Ahkavan D; Dang J; Dinca EB; Plaisier SB; Oderberg I; Lee Y; Chen Z; Caldwell JS; Xie Y; Loo JA; Seligson D; Chakravari A; Lee FY; Weinmann R; Cloughesy TF; Nelson SF; Bergers G; Graeber T; Furnari FB; James CD; Cavenee WK; Johns TG; Mischel PS
    Cancer Res; 2009 Sep; 69(17):6889-98. PubMed ID: 19690143
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Circular RNA-encoded oncogenic E-cadherin variant promotes glioblastoma tumorigenicity through activation of EGFR-STAT3 signalling.
    Gao X; Xia X; Li F; Zhang M; Zhou H; Wu X; Zhong J; Zhao Z; Zhao K; Liu D; Xiao F; Xu Q; Jiang T; Li B; Cheng SY; Zhang N
    Nat Cell Biol; 2021 Mar; 23(3):278-291. PubMed ID: 33664496
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Guanylate binding protein 1 is a novel effector of EGFR-driven invasion in glioblastoma.
    Li M; Mukasa A; Inda MM; Zhang J; Chin L; Cavenee W; Furnari F
    J Exp Med; 2011 Dec; 208(13):2657-73. PubMed ID: 22162832
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thyroid receptor-interacting protein 13 and EGFR form a feedforward loop promoting glioblastoma growth.
    Hu L; Shen D; Liang D; Shi J; Song C; Jiang K; Menglin Ren ; Du S; Cheng W; Ma J; Li S; Bi X; Barr MP; Fang Z; Xu Q; Li W; Piao H; Meng S
    Cancer Lett; 2020 Nov; 493():156-166. PubMed ID: 32860853
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mitogenic signalling in the absence of epidermal growth factor receptor activation in a human glioblastoma cell line.
    Wang M; Maier P; Wenz F; Giordano FA; Herskind C
    J Neurooncol; 2013 Dec; 115(3):323-31. PubMed ID: 24022637
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activation of multiple ERBB family receptors mediates glioblastoma cancer stem-like cell resistance to EGFR-targeted inhibition.
    Clark PA; Iida M; Treisman DM; Kalluri H; Ezhilan S; Zorniak M; Wheeler DL; Kuo JS
    Neoplasia; 2012 May; 14(5):420-8. PubMed ID: 22745588
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The endosomal pH regulator NHE9 is a driver of stemness in glioblastoma.
    Ko M; Makena MR; Schiapparelli P; Suarez-Meade P; Mekile AX; Lal B; Lopez-Bertoni H; Kozielski KL; Green JJ; Laterra J; Quiñones-Hinojosa A; Rao R
    PNAS Nexus; 2022 Mar; 1(1):pgac013. PubMed ID: 35387234
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epidermal growth factor receptor and ligand family expression and activity in glioblastoma.
    von Achenbach C; Weller M; Szabo E
    J Neurochem; 2018 Oct; 147(1):99-109. PubMed ID: 29953622
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting LRIG2 overcomes resistance to EGFR inhibitor in glioblastoma by modulating GAS6/AXL/SRC signaling.
    Dong M; Xiao Q; Hu J; Cheng F; Zhang P; Zong W; Tang Q; Li X; Mao F; He Y; Yu X; Wan F; Lei T; Guo D; Wang B
    Cancer Gene Ther; 2020 Dec; 27(12):878-897. PubMed ID: 31988476
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epidermal Growth Factor Receptor Extracellular Domain Mutations in Glioblastoma Present Opportunities for Clinical Imaging and Therapeutic Development.
    Binder ZA; Thorne AH; Bakas S; Wileyto EP; Bilello M; Akbari H; Rathore S; Ha SM; Zhang L; Ferguson CJ; Dahiya S; Bi WL; Reardon DA; Idbaih A; Felsberg J; Hentschel B; Weller M; Bagley SJ; Morrissette JJD; Nasrallah MP; Ma J; Zanca C; Scott AM; Orellana L; Davatzikos C; Furnari FB; O'Rourke DM
    Cancer Cell; 2018 Jul; 34(1):163-177.e7. PubMed ID: 29990498
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.